Kameel D. Farag
Known title: Interim CFOCIK: 0002093620
Associated companies
Transaction History
| AKTX | ▲ Buy | Grant | 1,728 | $13K | 8/17/2026 | View on chart |
| AKTX | ▲ Buy | Grant | 1,130 | $13K | 7/16/2026 | View on chart |
| AKTX | ▲ Buy | Grant | 1,570 | $13K | 6/24/2026 | View on chart |
| AKTX | ▲ Buy | Grant | 1,248 | $13K | 6/24/2026 | View on chart |
| AKTX | ▲ Buy | Grant | 1,395 | $13K | 6/24/2026 | View on chart |
| AKTX | ▲ Buy | Grant | 2,539 | $13K | 6/24/2026 | View on chart |
| AKTX | ▲ Buy | Grant | 3,725 | $13K | 6/24/2026 | View on chart |
| AKTX | ▲ Buy | Grant | 7,353 | $28K | 6/24/2026 | View on chart |
| AKTX | ▲ Buy | Grant | 1,000 | $13K | 6/24/2026 | View on chart |
| AKTX | ▲ Buy | Grant | 26,619 | $20K | 11/1/2025 | View on chart |
| AKTX | ▲ Buy | Grant | 32,000 | $24K | 11/1/2025 | View on chart |
| AKTX | ▲ Buy | Grant | 6,277 | $5K | 10/22/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Akari Therapeutics Files New Patent Application
Akari Therapeutics has submitted a new patent application to expand its intellectual property portfolio. This move is relevant as it aims to strengthen the company's long-term position in its therapeutic areas. The stock currently trades well below its 52-week high, reflecting the significant volatility seen in the sector.
Akari Therapeutics Files New Patent Application. Akari Therapeutics has submitted a new patent application to expand its intellectual property portfolio. This move is relevant as it aims to strengthen the company's long-term position in its therapeutic areas. The stock currently trades well below its 52-week high, reflecting the significant volatility seen in the sector.